BD Launches Neopak XtraFlow Glass Prefillable Syringe for Biologics | The Healthcare Technology Report.

Oct 14, 2024

Becton, Dickinson and Company (BD), a well-known pioneer in medical technology worldwide, announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe. The BD NeopakTM Glass Prefillable Syringe platform, which has been approved for over 24 indications, including the treatment of Crohn's disease and other uncommon disorders, is enhanced by this novel product. The XtraFlow syringe optimizes subcutaneous delivery of high-viscosity drug profiles while lowering injection force and time thanks to its thinner wall cannula and 8-millimeter needle. Pharmaceutical makers may now transcend the design constraints of conventional syringes thanks to this development.

BD is committed to enhancing healthcare delivery, diagnosis, and medical research worldwide. The organization, which employs over 70,000 people, is dedicated to improving the effectiveness and security of healthcare procedures. The BD Neopak Glass Prefillable Syringe platform's production capacity has increased sevenfold due to the recent extension of the manufacturing line in Le Pont-de-Claix, France. This increase strengthens BD's ability to address the increasing demand for biologic medicines. By supporting the administration of next-generation medicines like GLP-1s and antibodies, this calculated step strengthens BD's position as a leader in injectable solutions.

Please purchase a subscription to continue reading this article.

Read more